يعرض 1 - 9 نتائج من 9 نتيجة بحث عن '"Salva Ballabrera, Francesc"', وقت الاستعلام: 0.84s تنقيح النتائج
  1. 1
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Baraibar I, Salvà F, Ros J, Saoudi N, García-Álvarez A, Hernando J, Capdevila J, Castells MR, Tabernero J, Élez E Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. García A, Comas R, Castillo G, Sanchis M Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Martí M, Espín E, Dopazo C Servei de Cirurgia General i Digestiva, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Landolfi S Servei d’Anatomia Patològica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Navalpotro B Servei d’Oncologia Radioteràpica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Guevara J Servei d’Aparell Digestiu, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Nuciforo P, Vivancos A Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Translational Oncology;32; https://doi.org/10.1016/j.tranon.2023.101668Test; Baraibar I, García A, Salvà F, Ros J, Saoudi N, Comas R, et al. Impact of the COVID-19 pandemic in the early-onset colorectal cancer. Transl Oncol. 2023 Jun;32:101668.; https://hdl.handle.net/11351/9430Test; 000866211600326

  2. 2
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Baraibar I, Ros J, Saoudi N, Salvà F, Castells MR, Tabernero J, Élez E Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. García A Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: ESMO Open;8(2); https://doi.org/10.1016/j.esmoop.2023.101204Test; Baraibar I, Ros J, Saoudi N, Salvà F, García A, Castells MR, et al. Sex and gender perspectives in colorectal cancer. ESMO Open. 2023 Apr;8(2):101204.; https://hdl.handle.net/11351/9426Test

  3. 3
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Ros J Medical Oncology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Oncologia Medica, Dipartimento di Medicina di Precisione, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy. Balconi F Medical Oncology, University Hospital and University of Cagliari, Cagliari, Italy. Baraibar I, Saoudi Gonzalez N, Salva F, Tabernero J, Elez E Medical Oncology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Frontiers in Oncology;13; https://doi.org/10.3389/fonc.2023.1112276Test; Ros J, Balconi F, Baraibar I, Saoudi Gonzalez N, Salva F, Tabernero J, et al. Advances in immune checkpoint inhibitor combination strategies for microsatellite stable colorectal cancer. Front Oncol. 2023 Feb 2;13:1112276.; https://hdl.handle.net/11351/9188Test; 000936726600001

  4. 4
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Élez E, Argilés G, Sanz-Garcia E, Baraibar I, Salvà F, Noguerido A, Garcia A, Tabernero J Colorectal Cancer Program, Medical Oncology Department, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Mulet-Margalef N Colorectal Cancer Program, Medical Oncology Department, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Colorectal Cancer Unit, Medical Oncology Department, Catalan Institute of Oncology, L’Hospitalet de Llobregat, Barcelona, Spain. Sanso M Cancer Genomics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Genomics for Precision Oncology Laboratory, Fundació Institut d’Investigació Sanitària Illes Balears (IdISBa), Palma de Mallorca, Spain. Ruiz-Pace F, Comas R, Dienstmann R Oncology Data Science Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Mancuso FM Cancer Genomics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Research and Development Department, Universal Diagnostics S.L., Sevilla, Spain. Ros J, Martini G Colorectal Cancer Program, Medical Oncology Department, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy. Cuadra-Urteaga JL Colorectal Cancer Program, Medical Oncology Department, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Medical Oncology, IOB—Hospital Quirón, Barcelona, Spain. Fasani R, Jimenez J, Nuciforo P Molecular Oncology Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Aguilar S Molecular Prescreening Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Landolfi S, Hernández-Losa J Servei d’Anatomia Patològica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Braña I Medical Oncology Department, Research Unit for Molecular Therapy of Cancer, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Salazar R Colorectal Cancer Unit, Medical Oncology Department, Catalan Institute of Oncology, L’Hospitalet de Llobregat, Barcelona, Spain. Medical Oncology Department, Research Unit for Molecular Therapy of Cancer, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vivancos A Cancer Genomics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: International Journal of Molecular Sciences;24(1); https://doi.org/10.3390/ijms24010118Test; Élez E, Mulet-Margalef N, Sanso M, Ruiz-Pace F, Mancuso FM, Comas R, et al. A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy. Int J Mol Sci. 2022 Dec 21;24(1):118.; https://hdl.handle.net/11351/9154Test; 000909932600001

  5. 5
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Ros J Department of Medical Oncology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy. Saoudi N, Baraibar I, Salva F, Tabernero J, Elez E Department of Medical Oncology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Therapeutic Advances in Gastroenterology;15; https://doi.org/10.1177/17562848221110644Test; Ros J, Saoudi N, Baraibar I, Salva F, Tabernero J, Elez E. Encorafenib plus cetuximab for the treatment of BRAF-V600E-mutated metastatic colorectal cancer. Therap Adv Gastroenterol. 2022 Jul 4;15:1-14.; https://hdl.handle.net/11351/8352Test; 000827727300001

  6. 6
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, González Astorga B Hospital Universitario Clínico San Cecilio, Granada, Spain. Salvà Ballabrera F, Élez Fernández E Vall d’Hebron Hospital Universitari, Barcelona, Spain. Aranda Aguilar E Hospital Universitario Reina Sofía, Córdoba, Spain. García-Alfonso P Hospital General Universitario Gregorio Marañón, Madrid, Spain. González Flores E Hospital Universitario Virgen de Las Nieves, Granada, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Clinical and Translational Oncology;23; https://doi.org/10.1007/s12094-021-02568-yTest; González Astorga B, Salvà Ballabrera F, Aranda Aguilar E, Élez Fernández E, García-Alfonso P, González Flores E, et al. Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept. Clin Transl Oncol. 2021 Aug;23:1520–1528.; https://hdl.handle.net/11351/6884Test; 000621755500002

  7. 7
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Baraibar I, Saoudi N, Ros J, Salvà F, Tabernero J, Élez E Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Mirallas O Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Cancers;13(24); https://doi.org/10.3390/cancers13246311Test; Baraibar I, Mirallas O, Saoudi N, Ros J, Salvà F, Tabernero J, et al. Combined Treatment with Immunotherapy-Based Strategies for MSS Metastatic Colorectal Cancer. Cancers. 2021 Dec;13(24):6311.; https://hdl.handle.net/11351/7636Test; 000741497900001

  8. 8
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Ros J, Baraibar I, Salvà F, Argilés G, Élez E Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Sardo E Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Mulet N Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Department of Medical Oncology, Institut Català d’Oncologia, Barcelona, Spain. Martini G, Ciardiello D Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Medicine, Università degli Studi della Campania Luigi Vanvitelli, Naples, Caserta, Campania, Italy. Tabernero J Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. UVic-UCC, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Therapeutic Advances in Medical Oncology;13; https://doi.org/10.1177/1758835921992974Test; info:eu-repo/grantAgreement/ES/PE2013-2016/PI17%2F00947; info:eu-repo/grantAgreement/ES/PE2017-2020/PI20%2F00968; Ros J, Baraibar I, Sardo E, Mulet N, Salvà F, Argilés G, et al. BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer. Ther Adv Med Oncol. 2021 Jan;13:1–15.; https://hdl.handle.net/11351/7159Test; 000621944000001

  9. 9
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Martini G Università della Campania L. Vanvitelli, Naples. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Dienstmann R, Elez E Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Ros J, Baraibar I, Cuadra-Urteaga JL, Salva F, Mulet N, Argiles G, Tabernero J Vall d’Hebron Hospital Universitari, Barcelona, Spain. Ciardiello D Università della Campania L. Vanvitelli, Naples. Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Therapeutic Advances in Medical Oncology;12; https://doi.org/10.1177/1758835920936089Test; Martini G, Dienstmann R, Ros J, Baraibar I, Cuadra-Urteaga JL, Salva F, et al. Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer: Ther Adv Med Oncol. 2020 Jul 24;12:1–18.; https://hdl.handle.net/11351/6528Test; 000555770600001